Štork M - Search Results

1

[Heart transplantation and follow-up treatment with AL-amyloidosis in 5 patients].

Adam Z, Ozábalová E, Němec P, Bedáňová H, Kuman M, Krejčí J, Špinarová L, Žampachová V, Čermáková Z, Pour L, Krejčí M, Sanecká V, Štork M, Pika T, Straub J, Adamová D, Stavařová Y, Král Z, Mayer J. Adam Z, et al. Among authors: stork m. Vnitr Lek. 2018 Spring;64(4):441-449. Vnitr Lek. 2018. PMID: 29791180 Czech.

2

Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.

Sandecka V, Popkova T, Stork M, Maisnar V, Minarik J, Jungova A, Pavlicek P, Stejskal L, Pospisilova L, Heindorfer A, Obernauerova J, Gregora E, Sykora M, Ullrychova J, Wrobel M, Kessler P, Jelinek T, Kunovszki P, Bathija S, Gros B, Wilbertz S, Cai Q, Lam A, Spicka I. Sandecka V, et al. Among authors: stork m. Blood Cancer J. 2023 Sep 27;13(1):153. doi: 10.1038/s41408-023-00906-7. Blood Cancer J. 2023. PMID: 37752128 Free PMC article.

3

[Outcomes of AL-amyloidosis treatment with bortezomib, dexamethasone and cyclophosphamide or doxorubicin-containing regimens].

Adam Z, Stork M, Pour L, Krejčí M, Zahradová L, Sandecká V, Hájek R, Cermáková Z, Pospíšilová Y, Navrátil M, Král Z, Mayer J. Adam Z, et al. Among authors: stork m. Vnitr Lek. 2012 Dec;58(12):896-903. Vnitr Lek. 2012. PMID: 23427947 Czech.

4

[Use of new drugs within primary therapy of multiple myeloma].

Štork M, Krejčí M, Sandecká V, Král Z, Pour L. Štork M, et al. Vnitr Lek. 2016 Spring;62(5):413-22. Vnitr Lek. 2016. PMID: 27319235 Czech.

5

[Pomalidomide in the treatment of multiple myeloma - own experience and overview of literature].

Adam Z, Pour L, Krejčí M, Vetešníková E, Sandecká V, Štork M, Čermáková Z, Pourová E, Ševčíková S, Král Z, Mayer J. Adam Z, et al. Among authors: stork m. Vnitr Lek. 2016 Winter;62(12):962-968. Vnitr Lek. 2016. PMID: 28139124 Review. Czech.

6

[Osteoprotective therapy with bisphosphonates or denosumab in patients with multiple myeloma: benefit and risks].

Adam Z, Straub J, Krejčí M, Pour L, Brančíková D, Ostřížková L, Sandecká V, Štork M. Adam Z, et al. Among authors: stork m. Vnitr Lek. 2017 Summer;63(5):311-321. Vnitr Lek. 2017. PMID: 28726429 Review. Czech.

7

Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients.

Stork M, Sevcikova S, Adam Z, Krejci M, Sandecka V, Kral Z, Brozova L, Velichova R, Pour L. Stork M, et al. Neoplasma. 2018;65(4):585-591. doi: 10.4149/neo_2018_170519N363. Neoplasma. 2018. PMID: 29940759

8

Plasma Cell Leukemia – the Forgotten Disease.

Žárska M, Vrábel D, Bezdekova R, Štork M, Jarošová M, Adam Z, Krejčí M, Pour L, Ševčíková S. Žárska M, et al. Among authors: stork m. Klin Onkol. 2019 Winter;32(1):40-46. Klin Onkol. 2019. PMID: 30764628 Review. English.

9

Systemic inflammatory response with high CRP values as the dominant symptom of multiple myeloma.

Král Z, Adam Z, Folber F, Moulis M, Tomíška M, Říhová L, Štork M, Buliková A, Pour L, Krejčí M, Sandecká V, Koukalová R, Řehák Z, Čermáková Z. Král Z, et al. Among authors: stork m. Vnitr Lek. 2019 Winter;65(1):37-44. Vnitr Lek. 2019. PMID: 30823836 English.

10

Bortezomib and Thalidomide Treatment Results in Newly Diagnosed Transplant-Ineligible Multiple Myeloma Patients are Comparable in Long-Term Follow-Up.

Stork M, Sandecká V, Boichuk I, Adam Z, Krejci M, Brozova L, Sevcikova S, Pour L. Stork M, et al. Klin Onkol. 2019 Fall;32(6):445-452. doi: 10.14735/amko2019445. Klin Onkol. 2019. PMID: 31842563 English.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

156 results

Search Page